Hizentra® (immune globulin subcutaneous [human], 20%) – New orphan indication
March 15, 2018 - The FDA approved CSL Behring’s Hizentra (immune globulin [human] 20%) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
Top